Investigating therapeutic candidates and the use of preclinical models to predict treatment response in melanoma
Metadata
Vis metadataFinnes i følgende samling
- Institutt for klinisk medisin [10814]
- CRIStin høstingsarkiv [31446]
Sammendrag
Sammendrag ikke registrert.Artikkelliste
I. A three-dimensional ex vivo viability assay reveals a strong correlation between response to targeted inhibitors and mutation status in melanoma lymph node metastases. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM. Translational Oncology. 2019 Jul;12(7):951-958. The paper is included in the thesis, and is also available at: https://doi.org/10.1016/j.tranon.2019.04.001 |
II. Targeting AXL and the DNA damage response pathway as a novel therapeutic strategy in melanoma. Flem-Karlsen K, McFadden E, Omar N, Haugen MH, Øy GF, Ryder T, Gullestad HP, Hermann R, Mælandsmo GM, Flørenes VA. Molecular Cancer Therapeutics. 2020 19(3):895-905. An author version is included in the thesis, the published version is available at: https://doi.org/10.1158/1535-7163.MCT-19-0290 |
III. Soluble AXL as a marker of disease progression and survival in melanoma. Flem-Karlsen K, Nyakas M, McFadden E, Wernhoff P, Farstad IN, Flørenes VA, Mælandsmo GM. PLOS ONE. 2020, 15 (1):e0227187. An author version is included in the thesis, the published version is available at: https://doi.org/10.1371/journal.pone.0227187 |
IV. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE. Scientific Reports. 2019 April;9(1):5839. The paper is included in the thesis, and is also available at: https://doi.org/10.1038/s41598-019-42303-w |